PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer

Overview of attention for article published in Frontiers in immunology, December 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter: 9 X users

Citations

dimensions_citation: 22 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 10 X posts from 9 X users, with an upper bound of 45,066 followers.

New article: PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer https://t.co/t8jz4rrcWK #pancreaticcancer #oncology https://t.co/WcrlGgIbXW

03 Jan 2022

Reply Repost Favourite

RT @FrontImmunol: New Research: PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer: De…

18 Dec 2021

Reply Repost Favourite

RT @FrontImmunol: New Research: PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer: De…

18 Dec 2021

Reply Repost Favourite

New Research: PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer: Despite recent improvements in treatment modalities, pancreatic cancer remains a highly lethal tumor with mortality rate… https://t.co/yq

18 Dec 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 6 additional X posts.